keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day 3
keyboard_arrow_leftSearch & Filter
search
Streams
Day 3
search
Streams
8:00am - 8:10am
Registration and Coffee
Plenary Session
Showing 1 of 1 Streams
Plenary Sessions
8:10am - 8:15am
Chairperson’s Remarks: Plenary Day 3
- Ed Yaworski - Chief Technology Officer, Genevant Sciences Corp
8:15am - 8:45am
Modulation of Host Immunity in the Airways with Interferon Lambda Encoding mRNA
- Christian Plank, PhD - Chief Technology Officer, Ethris GmbH
8:45am - 9:15am
Digital PCR for the Analysis of RNA Quality Parameters
- Andreas Czech, PhD - Associate Director RNA Analytics, BioNTech SE
9:15am - 9:45am
Fine Tuning a PCR based mRNA Manufacturing Platform for each mRNA Sequence
- Aditi Mehta, PhD - Associate Director, Head of mRNA Process & Deliver, Merck KGaA
9:45am - 10:15am
Lipid Nanoparticles to Enable Clinical Development of mRNA-based Therapeutics
- Ying Tam, Ph.D. - Chief Scientific Officer, Acuitas Therapeutics
10:15am - 10:55am
Networking Refreshment Break with Poster and Exhibit Viewing
Concurrent Conference Tracks
Showing 2 of 2 Streams
Track #1
Track #2
10:55am - 11:00am
Chairperson’s Remarks: Track 1
- Akiko Yanagiya, PhD - Scientist, Arcalis
11:00am - 11:30am
Preclinical Data for STK-002, an Antisense Oligonucleotide Being Developed for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
- Shobha Ravipaty, PhD - Director, Stoke Therapeutics
11:30am - 12:00pm
Discovery and Delivery of Oligonucleotide Therapeutics
- Jayaprakash Nair, PhD - Vice President, Research, Chemistry and Delivery Science, Alnylam Pharmaceuticals
12:00pm - 12:30pm
From Bench to Bedside: Development of a GalXC-Plus siRNA, DCR-STAT3, for Immunotherapy in Refractory Cancer Patients
- Jennifer Lockridge, PhD - VP, Dicerna TRU Early Development, Novo Nordisk
10:55am - 11:00am
Chairperson’s Remarks: Track 2
- Ed Yaworski - Chief Technology Officer, Genevant Sciences Corp
11:00am - 11:30am
Discovery of Macrocycles for Delivery of RNA and Targeted Radiopharmaceuticals
- Ratmir Derda, PhD - Founder and CSO, 48Hour Discovery and Associate Professor, Department of Chemistry, University of Alberta
11:30am - 12:00pm
Redefining Non-viral Delivery for Novel Genomic Medicines with Tissue-targeted Lipid Nanoparticle (ttLNP) Platform
- Kate Zhang, Ph.D. - Chief Scientific Officer, Hopewell Therapeutics
12:00pm - 12:30pm
Tuning Lipid Nanoparticles for Specific Applications
- Ed Yaworski - Chief Technology Officer, Genevant Sciences Corp
12:30pm - 1:30pm
Networking Luncheon with Poster and Exhibit Viewing
Showing 2 of 2 Streams
Track #1
Track #2
1:30pm - 1:35pm
Chairperson’s Remarks: Track 1
- Akiko Yanagiya, PhD - Scientist, Arcalis
1:35pm - 2:05pm
Examples of Antisense Oligonucleotides that Target the Immunosuppressive Tumor Microenvironment for Treatment of Cancer
- Frank Jaschinski, Ph.D. - Chief Scientific Officer, Secarna Pharmaceuticals
2:05pm - 2:35pm
CIVI 008: An Orally Active LNA Drug Against PCSK9
- Henrik Oerum, PhD - Founder and Chief Scientific Officer, CiVi Biopharma Inc.
2:35pm - 3:05pm
Lymph Node Macrophages Drive Innate Immune Responses to Enhance the Anti-tumor Efficacy of mRNA Vaccines
- Kenji Kubara - Scientist, Emerging Modality Generation, Eisai. Co., Ltd.
1:30pm - 1:35pm
Chairperson’s Remarks: Track 2
- El Djouhar Rekaï, PhD - Head of Process Development & Manufacturing Life cycle Management, PolyPeptide Group
1:35pm - 2:05pm
Gate2Brain Shuttles, Going Beyond the Transport of Small Molecules
- Meritxell Teixidó, PhD - CEO and CSO, Gate2Brain
2:05pm - 2:35pm
Control Strategy Set-Up for Efficient & Safe Large Scale Peptide Manufacturing Process
- El Djouhar Rekaï, PhD - Head of Process Development & Manufacturing Life cycle Management, PolyPeptide Group
2:35pm - 3:05pm
In-line Monitoring Method Integrating Flow Chemistry for Peptide/Nucleotide Synthesis
- Pengyu Xu, Ph.D. - President and Representative Director, SynCrest Inc.
3:05pm - 3:35pm
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 2 of 2 Streams
Track #1
Track #2
3:35pm - 4:05pm
Chimeric PN-containing Oligonucleotides Yield Exon Skipping in Preclinical Models and Boys with Duchenne Muscular Dystrophy
- Michael Byrne, Ph.D. - Vice President, In Vivo and CNS Biology, Wave Life Sciences
4:05pm - 4:35pm
Key Elements of a Well Composed Nonclinical Section of an IND Application
- Emily Place, PhD - Senior Consultant, Aclairo Pharmaceutical Development Group
4:35pm - 5:05pm
Clinically Effective Scar Treatment via a siRNA Transdermal Gene Silencing Technology: From Bench to Bedside and Beyond
- Timothy Tan, PhD - Associate Professor, Nanyang Technological University and Founder, RNAscence Biotech Pte Ltd.
3:35pm - 4:05pm
Flow SPPS – Towards Greener and More Efficient Peptide Manufacturing
- Eike-Fabian Sachs, PhD - Head of Development Frankfurt, CordenPharma International GmbH
4:05pm - 4:35pm
Biocatalysis for Green Manufacturing of Amino Acids
- Wendy Hartsock, PhD - Director of Strategic Partnerships, Aralez Bio
4:35pm - 5:05pm
Individualised Cancer Vaccines: Developing a High-throughput cGMP Manufacturing Philosophy
- Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group
5:05pm - 5:10pm
Close of Conference
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Choose Day